Recursion says Sanofi options a first-in-class immunology development candidate from their AI collaboration, triggering a $10 million milestone

In a 15 October 2026 release that also announced a $200 million follow-on offering and clinical data updates, Recursion reported that Sanofi optioned a potential first-in-class oral small-molecule development candidate for a dual target in inflammatory disease from their collaboration. The option triggered a $10 million milestone, bringing upfront and milestone payments to $144 million to date, with more than $300 million in further milestones possible. Company-reported; added as an older item that Community lacked.